Metropolis Healthcare Limited (METROPOLIS) Financial Results — Revenue ₹1.38 L Cr

Revenue: ₹1.38 L CrNet Profit: ₹4,323.62 Cr

📢 Key Event
Board approved FY2026 audited results, interim dividend, and auditor change to Deloitte Haskins & Sells.

🔄 What Changed
Net profit increased to ₹4323.62 crores; auditor changed from B S R & Co. LLP to Deloitte Haskins & Sells; Dr. Nilesh Shah moved to advisory role; 3:1 bonus issue announced.

🔮 What's Next
The company did not provide explicit future financial guidance or deadlines in the document.

💡 Investor Takeaway
Shareholders receive a ₹1 interim dividend and benefit from a new auditor appointment, while management changes signal leadership transition.

Metropolis Healthcare reported a net profit of ₹4323.62 crores for FY2025-26, up from ₹21170.01 lakhs last year, with earnings per share at [amount context mismatch] and an interim dividend of ₹1 per share approved on May 19, 2026, payable by June 19. The company appointed Deloitte Haskins & Sells as its new statutory auditor, replacing B S R & Co. LLP, effective May 13, 2026, while Dr. Nilesh Shah transitioned to an advisory role. The auditor confirmed an unmodified opinion on consolidated financials, which included unadjusted subsidiary figures totaling ₹5,763.67 lakhs in assets and ₹889.54 lakhs in net profit before consolidation adjustments. Business acquisitions in pathology and diagnostics added ₹11,611 lakhs to purchase consideration, and a 3:1 bonus issue was announced. The filing also noted regulatory impacts from new labour codes and a reduced tax demand of ₹3,880 lakhs.

📄 View Original Announcement (PDF)

📊 Stock Analysis — METROPOLIS ✨ Ask AI About This